Ganymed Pharmaceuticals AG is a biopharmaceutical company developing a new class of immunotherapeutic cancer drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects. Ganymed is a private company that was founded in 2001. Its majority shareholder is ATS Beteiligungsverwaltung GmbH. Other investors include MIG Fonds, Future Capital AG, FCP Gany GmbH, and private individuals. For further information, please visit us at: http://www.ganymed.ag
NPR/16/0006/APEL
October 2016
CONTACT: Contacts for inquiries or additional information: Astellas PharmaInc., Corporate Communications, TEL: +81-3-3244-3201 FAX: +81-3-5201-7473,US Media:Stefanie Prodouz, TEL: +1 (224) 205-5943, stefanie.prodouz@astellas.com,EMEA Media: Jo Taylor, TEL: +44 (7467) 736751, jo.taylor@astellas.com,Ganymed Pharmaceutical AG, Luc St-Onge, TEL: +49 (6131) 1440 195,l.st-onge@ganymed.ag
